A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, phase II study to evaluate the efficacy and safety of
Envafolimab in subjects with locally advanced/unresectable (Stage III) non-small cell lung
cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.